| Race, White, n (%) |
5 (100) |
41(69.5) |
0.34 |
| Age at start of ITI, years, median (Q1,Q3) |
1.1 (0.8,1.8) |
3.4 (1.5, 10.3) |
0.12 |
| Time from inhibitor onset to start ITI, years, median (Q1,Q3) |
1.1 (0.1, 15.6) |
0.7 (0.2, 2.7) |
0.80 |
| ≥ 2 years, n (%) |
1 (20.0) |
13 (22.0) |
1.0 |
| Historical peak titer, BU/ml, median (Q1,Q3) |
25.9 (3,27) |
9.8 (4,34) |
0.79 |
| ≥ 200 BU/ml, n (%) |
0 |
3 (5.1) |
- |
| Titer at start ITI, BU/ml, median (Q1,Q3) |
2.0 (1.9,4) |
2.1 (1,5.5) |
0.59 |
| Duration of ITI, years, median (Q1,Q3) |
2.2 (1.2, 2.4) |
1.1 (0,5.2) |
0.39 |
| Peak titer during ITI ≥ 100 BU/ml, n (%) |
2 (40) |
4 (6.8) |
0.07 |
| FVIII recovery level, %, median (Q1,Q3) |
79 (75,85) |
85 (71,98) |
0.63 |
| Tolerance Criteria Met |
|
|
0.23 |
| Titer and FVIII recovery only |
1 (20) |
34 (57.6) |
|
| Titer, FVIII recovery, and half-life |
4 (80) |
24 (40.7) |
|
| Time to relapse, years, median (Q1,Q3) |
0.42 (0.39,0.56) |
3.8 (1.8,7.0) |
0.001 |
